UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC, Petitioner,

v.

OPIANT PHARMACEUTICALS, INC., Patent Owner.

Case IPR2019-00688 U.S. Patent 9,468,747

PATENT OWNER'S OBJECTIONS TO EVIDENCE



Pursuant to 37 C.F.R. § 42.64, Patent Owner Opiant Pharmaceuticals, Inc. submits the following objections to the exhibits filed by Nalox-1 Pharmaceuticals, LLC on February 19, 2019.

Patent Owner objects to **Exhibit 1004** under Federal Rules of Evidence ("FRE") 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1005** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1006** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1012** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1017** under FRE 401, 402, 403, and 901 as irrelevant and not authenticated.

Patent Owner objects to **Exhibit 1018** under FRE 401, 402, 403, 801, 802, 805, and 901 as irrelevant and inadmissible hearsay and not authenticated.

Patent Owner objects to **Exhibit 1024** under FRE 106, 401, 402, and 403 as irrelevant and incomplete.

Patent Owner objects to **Exhibit 1025** under FRE 106, 401, 402, 403, and 901 as irrelevant, incomplete, and not authenticated.



Patent Owner objects to **Exhibit 1039** FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1043** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1044** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1045** under FRE 106, 401, 402, and 403 as irrelevant and incomplete.

Patent Owner objects to **Exhibit 1050** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1054** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1063** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1065** under FRE 106, 401, 402, and 403 as incomplete and an improper compilation of multiple documents.

Patent Owner objects to **Exhibit 1066** under FRE 106, 401, 402, and 403 as incomplete.



Date: September 23, 2019 Respectfully submitted,

/Jessica Tyrus Mackay/

Robert F. Green (Reg. No. 27,555)
Jessica Tyrus Mackay (Reg. No. 64,742)
GREEN, GRIFFITH & BORG-BREEN, LLP
676 North Michigan Avenue
Suite 3900
Chicago, IL 60611
(313) 883-8000
jmackay@greengriffith.com

Counsel for Patent Owner Opiant Pharmaceuticals, Inc.



CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true and correct copy of the foregoing was served on September 23, 2019, by delivering a copy via electronic mail on the following attorneys of record:

Yelee Y. Kim
Janine A. Carlan
Richard Berman
Bradford Frese
Christopher Yaen
ARENT FOX LLP
1717 K Street NW
Washington, DC 20036
Yelee.Kim@arentfox.com
Janine.Carlan@arentfox.com
Richard.Berman@arentfox.com
Bradford.Frese@arentfox.com
Christopher.Yaen@arentfox.com

/Jessica Tyrus Mackay/ Jessica Tyrus Mackay (Reg. No. 64,742)

